Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O60840: Variant p.Ile756Thr

Voltage-dependent L-type calcium channel subunit alpha-1F
Gene: CACNA1F
Feedback?
Variant information Variant position: help 756 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Isoleucine (I) to Threonine (T) at position 756 (I756T, p.Ile756Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (I) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CSNB2A; increases the number of mutant channels open at physiologic membrane potential and allows for persistent Ca(2+) entry due to reduced channel inactivation resulting in a gain-of-function defect. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 756 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1977 The length of the canonical sequence.
Location on the sequence: help IYFIILFICGNYILLNVFLA I AVDNLASGDAGTAKDKGGEK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         IYFIILFICGNYILLNVFLAIAVDNLASGDAGTAKDKGGEK

Mouse                         VYFIILFICGNYILLNVFLAIAVDNLASGDAGTAKDKGREK
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1977 Voltage-dependent L-type calcium channel subunit alpha-1F
Transmembrane 734 – 758 Helical; Name=S6 of repeat II
Repeat 515 – 761 II



Literature citations
A CACNA1F mutation identified in an X-linked retinal disorder shifts the voltage dependence of Cav1.4 channel activation.
Hemara-Wahanui A.; Berjukow S.; Hope C.I.; Dearden P.K.; Wu S.-B.; Wilson-Wheeler J.; Sharp D.M.; Lundon-Treweek P.; Clover G.M.; Hoda J.-C.; Striessnig J.; Marksteiner R.; Hering S.; Maw M.A.;
Proc. Natl. Acad. Sci. U.S.A. 102:7553-7558(2005)
Cited for: VARIANT CSNB2A THR-756; CHARACTERIZATION OF VARIANT CSNB2A THR-756;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.